标题：LIFR基因mRNA表达对乳腺癌患者预后的判断价值

      作者：孙向飞 1，周喜春 1，陈小波 2    1.西安交通大学医学院附属西安市中心医院肿瘤科，陕西 西安 710000；2.西安交通大学第一附属医院放疗科/消毒供应中心，陕西 西安 710000

      卷次： 2020年31卷23期

      【摘要】 目的 探讨LIFR基因mRNA表达情况与乳腺癌患者预后的关系。方法 通过Kaplan-Meier Plotter数据分析工具对截止2019年11月1日收录在GEO数据库中登记的乳腺癌组织中LIFR基因mRNA表达情况与患者总生存期及无复发生存期之间的关系进行分析。结果 整体样本分析中，LIFR基因mRNA的高表达与乳腺癌患者更好的总生存时间(OS)(HR：0.7，95%Cl：0.57~0.87，P=0.001 2)和无复发生存率(RFS) (HR：0.7，95%CI：0.63~0.78，P=0.000 0)呈正相关；亚组分析中，OS方面，LIFR基因mRNA的高表达在Luminial B型亚组患者中与更好的OS呈正相关性(HR：0.66，95%CI：0.45~0.96，P=0.029)，而在癌细胞病理分级Ⅰ级的亚组患者中与更差的OS呈正相关性(HR：7.57，95%CI：1.01~56.76，P=0.02)，其余亚组分析中OS比较差异均无统计学意义(P>0.05)；RFS方面，LIFR基因mRNA的高表达在Luminal A型、Luminal B型、Basal-like型三种亚型的患者群中与更好的RFS呈正相关，即Luminal A型 (HR：0.69，95% CI：0.57~0.84，P=0.000 15)、Luminal B型 (HR：0.68，95% CI：0.56~0.82，P=0.000 0)、Basal-like (HR：0.66，95%CI：0.52~0.85，P=0.001 4)，但在Her-2阳性的亚组中，OS及RFS比较差异均无统计学意义(P>0.05)。结论 LIFR基因mRNA的高表达在乳腺癌患者整体人群预示着更好的RFS及OS，可作为乳腺癌患者预后的预测因子，但亚组分析中，这种预后指示作用可能有差别，这其中的内在机制仍需继续深入探究。
      【关键词】 乳腺癌；白血病抑制因子受体；信使RNA；TP53；淋巴结转移
      【中图分类号】 R737.9 【文献标识码】 A 【文章编号】 1003—6350（2020）23—3046—05

Prognostic values of LIFR mRNA expression in breast cancer patients.
SUN Xiang-fei 1, ZHOU Xi-chun 1, CHENXiao-bo 2. 1.Department of Oncology, Xi'an Central Hospital Affiliated to the Medicine College of Xi'an JiaotongUniversity, Xi'an 710000, Shaanxi, CHINA; 2. Department of Radiotherapy/Disinfection Supply Center, the First AffiliatedHospital of Xi'an Jiaotong University, Xi'an 710000, Shaanxi, CHINA
【Abstract】 Objective To investigate the relationship between LIFR mRNA expression and prognosis of pa-tients with breast cancer. Methods The Kaplan-Meier Plotter data analysis tool was used to analyze the relationship be-tween the LIFR gene mRNA expression in breast cancer tissues registered in the GEO database until November 1, 2019and the overall survival (OS) and recurrence-free survival (RFS) of patients. Results In the overall sample analysis,high mRNA expression of LIFR gene were associated with better OS (HR: 0.7, 95%CI: 0.57-0.87, P=0.001 2) and RFS(HR: 0.7, 95%CI: 0.63-0.78, P=0.000 0). In the subgroup analysis, in terms of OS, the high expression of LIFR genemRNA was positively correlated with better OS in Luminial B subgroup patients (HR: 0.66, 95% CI: 0.45-0.96, P=0.029), and the subgroup of patients with cancer cell pathological grade Ⅰ was positively correlated with worse OS(HR: 7.57, 95%CI: 1.01-56.76, P=0.02). There was no statistically significant difference in OS among the other sub-groups (P>0.05). In terms of RFS, the high expression of LIFR gene mRNA in the three subtypes of Luminal A, LuminalB, and Basal-like is positively correlated with better RFS: Luminal A (HR: 0.69, 95%CI: 0.57-0.84, P=0.000 15), Lumi-nal B type (HR: 0.68, 95%CI: 0.56-0.82, P=0.000 0), Basal-like (HR: 0.66, 95%CI: 0.52-0.85, P=0.001 4); but in theHer-2 positive subgroup, there was no statistically significant difference in OS and RFS (P>0.05). Conclusion Thehigh expression of LIFR gene mRNA predicts better RFS and OS in the whole population of breast cancer patients, andcan be used as a predictor of prognosis in breast cancer patients. However, in subgroup analysis, this prognostic resultsmay be different, thus more studies are needed to explore the mechanism.
      【Key words】 Breast cancer; LIFR; mRNA; TP53; Lymph node metastasis